Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

39.72
-1.2600-3.07%
Post-market: 39.41-0.3120-0.79%16:02 EDT
Volume:2.45M
Turnover:97.40M
Market Cap:5.34B
PE:-11.41
High:41.35
Open:40.61
Low:39.16
Close:40.98
52wk High:49.70
52wk Low:8.70
Shares:134.37M
Float Shares:131.11M
Volume Ratio:1.56
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.81
PE(LYR):-19.28

Loading ...

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys

Reuters
·
Jun 23

Definium Therapeutics Inc : Canaccord Genuity Raises Target Price to $60 From $38

THOMSON REUTERS
·
Jun 23

Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ

Dow Jones
·
Jun 23

Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD

Reuters
·
Jun 23

Small U.S. Stocks Close Mixed As Definium Therapeutics Leads, Butterfly Network Lags

Dow Jones
·
Jun 23

Definium Therapeutics Reports $500 Million Public Offering

MT Newswires Live
·
Jun 23

Definium Therapeutics offers to sell $500M in common stock

TIPRANKS
·
Jun 23

Definium Therapeutics plans USD 500 million follow-on stock offering

Reuters
·
Jun 23

Definium Therapeutics, Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
Jun 23

Definium Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 23

Top Midday Gainers

MT Newswires Live
·
Jun 23

Canaccord ups Definium Therapeutics target to $60, calls DT120 ‘solid contender’

TIPRANKS
·
Jun 23

Definium Therapeutics rises 55.9%

TIPRANKS
·
Jun 23

RBC Capital Adjusts Price Target on Definium Therapeutics to $57 From $36, Maintains Outperform Rating

MT Newswires Live
·
Jun 23

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

TIPRANKS
·
Jun 22

Definium Therapeutics price target raised to $60 from $40 at Oppenheimer

TIPRANKS
·
Jun 22

Definium Therapeutics price target raised to $57 from $36 at RBC Capital

TIPRANKS
·
Jun 22

Definium Therapeutics Stock (DFTX) Rockets on a Phase 3 Trial Win

TIPRANKS
·
Jun 22

RBC Capital says would buy Definium Therapeutics after Phase III data

TIPRANKS
·
Jun 22

Definium Therapeutics DT120 data exceeds expectations, says Stifel

TIPRANKS
·
Jun 22